The impact of population ageing on the burden of chronic kidney disease
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 2×
“54).”
InfluentialKDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530 · cited 7×
“To estimate the absolute risk of progression to kidney failure in individuals with CKD G3–G5, KDIGO recommends using an externally validated risk equation such as the Kidney Failure Risk Equation 32,35 .”
Influential2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485 · cited 3×
“Similar stabilization of eGFR with SGLT2 inhibitors was observed in patients with CKD owing to diverse causes and albuminuria 30 mg/g 100,101,107,111,112,117,118 (Fig.”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146 · cited 1×
“As diabetes mainly affects older individuals 59 and kidney damage typically occurs 5–15 years after diabetes onset, the rise in the burden of diabetes is expected to lead to a parallel rise in the burden of CKD, unless the implementation of preventive measures is substantially increased.”
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Zhou, B., Lu, Y., Hajifathalian, K., Bentham, J., Di Cesare, M., Danaei, G., Bixby, H., Cowan, M., Ali, M., Taddei, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00618-8 · Cited by 4,311
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Stevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
Mills, K. T., Bundy, J. D., Kelly, T. N., Reed, J. E., Kearney, P. M., Reynolds, K., Chen, J., & He, J. (2016) · Circulation · doi:10.1161/circulationaha.115.018912 · Cited by 3,531
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935 · cited 1×
“Other new agents have been tested only for certain aetiologies of CKD 109,133,155,156,159,162 (Supplementary Table 2).”
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898 · cited 1×
“Diabetes continues to be the leading cause of CKD worldwide 50–52 (Fig.”
Lloyd-Jones, D. M., Allen, N. B., Anderson, C. A. M., Black, T., Brewer, L. C., Foraker, R. E., Grandner, M. A., Lavretsky, H., Perak, A. M., Sharma, G., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001078 · Cited by 2,785
Empagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Zhou, B., Bentham, J., Di Cesare, M., Bixby, H., Danaei, G., Cowan, M. J., Paciorek, C. J., Singh, G., Hajifathalian, K., Bennett, J. E., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31919-5 · Cited by 2,579
Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015
Forouzanfar, M. H., Liu, P., Roth, G. A., Ng, M., Biryukov, S., Marczak, L., Alexander, L., Estep, K., Hassen Abate, K., Akinyemiju, T. F., et al. (2017) · JAMA · doi:10.1001/jama.2016.19043 · Cited by 2,381 · cited 1×
“LMICs bear a disproportionate burden of diabetes, with the prevalence increasing at a much faster rate than in HICs 10,55–58 .”
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208 · cited 1×
“However, compliance with lifestyle interventions is limited owing to multiple factors, including socioeconomic issues 121 .”
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099 · cited 1×
“The FLOW trial of semaglu-tide in participants with CKD (UACR >100 mg/g) and T2DM was stopped prematurely owing to efficacy for kidney, cardiovascular and all-cause mortality outcomes 160,163,164 .”
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814 · cited 1×
“Other new agents have been tested only for certain aetiologies of CKD 109,133,155,156,159,162 (Supplementary Table 2).”
Changes in diabetes-related complications in the United States, 1990-2010
Gregg, E. W., Li, Y., Wang, J., Rios Burrows, N., Ali, M. K., Rolka, D., Williams, D. E., & Geiss, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310799 · Cited by 1,749 · cited 1×
“The diabetes complication that showed the smallest decline in incidence between 1990 and 2010 was kidney failure 124 This trial enrolled participants with type 2 diabetes mellitus and high cardiovascular risk, most of whom did not meet the KDIGO eGFR and albuminuria thresholds for diagnosis of CKD…”
Global epidemiology and outcomes of acute kidney injury
Hoste, E. A. J., Kellum, J. A., Selby, N. M., Zarbock, A., Palevsky, P. M., Bagshaw, S. M., Goldstein, S. L., Cerdá, J., & Chawla, L. S. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0052-0 · Cited by 1,486
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001186 · Cited by 1,405
Agarwal, R., Filippatos, G., Pitt, B., Anker, S. D., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Gebel, M., Ruilope, L. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab777 · Cited by 1,317
Khan, S. S., Coresh, J., Pencina, M. J., Ndumele, C. E., Rangaswami, J., Chow, S. L., Palaniappan, L. P., Sperling, L. S., Virani, S. S., Ho, J. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001191 · Cited by 797
Murtagh, F. E. M., Marsh, J. E., Donohoe, P., Ekbal, N. J., Sheerin, N. S., & Harris, F. E. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm153 · Cited by 643
Amini, M., Zayeri, F., & Salehi, M. (2021) · BMC Public Health · doi:10.1186/s12889-021-10429-0 · Cited by 636 · cited 1×
“76,77).”
Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality
Tian, Y. E., Cropley, V., Maier, A. B., Lautenschlager, N. T., Breakspear, M., & Zalesky, A. (2023) · Nature Medicine · doi:10.1038/s41591-023-02296-6 · Cited by 618 · cited 1×
“Biological ageing is heterogeneous between and within individuals 113,114 .”
Garovic, V. D., Dechend, R., Easterling, T., Karumanchi, S. A., McMurtry Baird, S., Magee, L. A., Rana, S., Vermunt, J. V., August, P., & on behalf of the American Heart Association Council on Hypertension; Council on the Kidney in Cardiovascular Disease, K. I. H. D. S. C. C. O. A. (2022) · Hypertension · doi:10.1161/hyp.0000000000000208 · Cited by 598
Long-term complications in youth-onset type 2 diabetes
TODAY Study Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100165 · Cited by 546 · cited 1×
“However, the long-term cumulative incidence of CKD in people with T2DM may be as high as 54% 126 .”
Renal Aging: Causes and Consequences
O’Sullivan, E. D., Hughes, J., & Ferenbach, D. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121308 · Cited by 484 · cited 1×
“Age-related structural and functional changes that reduce kidney function and kidney reserve result in increased susceptibility to AKI and the subsequent development of CKD 90 , as well as poorer AKI recovery 91,92 .”
NHSR 158. National Health and Nutrition Examination Survey 2017–March 2020 Pre-pandemic Data Files
Bryan, S., Afful, J., Carroll, M., Te-Ching, C., Orlando, D., Fink, S., & Fryar, C. (2021) · doi:10.15620/cdc:106273 · Cited by 479
Obesity and related consequences to ageing
Jura, M., & Kozak, L. P. (2016) · AGE · doi:10.1007/s11357-016-9884-3 · Cited by 473
Fletcher, B. R., Damery, S., Aiyegbusi, O. L., Anderson, N., Calvert, M., Cockwell, P., Ferguson, J., Horton, M., Paap, M. C. S., Sidey-Gibbons, C., et al. (2022) · PLOS Medicine · doi:10.1371/journal.pmed.1003954 · Cited by 414 · cited 9×
“Interventions that maintain or improve the QoL of older patients, including pain management and palliative care services, should also be made available.”
InfluentialWriting Group for the CKD Prognosis Consortium, Appel, L. J., Grams, M., Woodward, M., Harris, K., Arima, H., Chalmers, J., Yatsuya, H., Tamakoshi, K., Li, Y., et al. (2023) · JAMA · doi:10.1001/jama.2023.17002 · Cited by 396 · cited 2×
“In both age groups, individuals with eGFR 60 ml/min/1.73 m 2 and albuminuria 30 mg/g (CKD category G3, A1) had consistently elevated relative risks of adverse outcomes compared with individuals with normal kidney function 34 .”
InfluentialYoshimura, Y., Wakabayashi, H., Yamada, M., Kim, H., Harada, A., & Arai, H. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.03.019 · Cited by 365 · cited 1×
“Although no recommended pharmacological treatments exist, exercise training and nutritional supplementation are widely accepted to be key interventions to maintain skeletal muscle mass and strength in patients with sarcopenia 183 .”
Neuen, B. L., Heerspink, H. J. L., Vart, P., Claggett, B. L., Fletcher, R. A., Arnott, C., de Oliveira Costa, J., Falster, M. O., Pearson, S.-A., Mahaffey, K. W., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067584 · Cited by 358 · cited 1×
“…on risk of death; combination therapy with SGLT2 inhibitors, GLP1RAs and the nsMRA may delay all-cause death by 2.4 years (95% CI 1.4–3.4), major adverse cardiovascular events by 3.2 years (95% CI 2.1–4.3) and CKD progression by 5.5 years (95% CI 4.0–6.7), compared with conventional therapy 173 .”
InfluentialRossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad009 · Cited by 242 · cited 2×
“The FLOW trial of semaglu-tide in participants with CKD (UACR >100 mg/g) and T2DM was stopped prematurely owing to efficacy for kidney, cardiovascular and all-cause mortality outcomes 160,163,164 .”
Assessing cognitive decline in the aging brain: lessons from rodent and human studies
Brito, D. V. C., Esteves, F., Rajado, A. T., Silva, N., ALFA score Consortium, Andrade, R., Apolónio, J., Calado, S., Faleiro, L., Matos, C., et al. (2023) · npj Aging · doi:10.1038/s41514-023-00120-6 · Cited by 177
Glycemia reduction in type 2 diabetes–microvascular and cardiovascular outcomes
The GRADE Study Research Group (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200436 · Cited by 159 · cited 1×
“A clinical trial in participants with T2DM showed no differences between the effect of the glucose-lowering drugs insulin glargine, glimepiride, liraglutide or sitagliptin combined with metformin on albuminuria or kidney impairment during a mean follow-up of 5 years 132 .”
Beddhu, S., Greene, T., Boucher, R., Cushman, W. C., Wei, G., Stoddard, G., Ix, J. H., Chonchol, M., Kramer, H., Cheung, A. K., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30099-8 · Cited by 128 · cited 1×
“Intensive blood pressure control has been associated with an increased incidence of CKD, highlighting the need to understand the long-term consequences of antihypertensive treatment-related decreases in eGFR 131 .”
Michos, E. D., Bakris, G. L., Rodbard, H. W., & Tuttle, K. R. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100502 · Cited by 125
Incidence of chronic kidney disease among adults with diabetes, 2015-2020
Tuttle, K. R., Jones, C. R., Daratha, K. B., Koyama, A. K., Nicholas, S. B., Alicic, R. Z., Duru, O. K., Neumiller, J. J., Norris, K. C., Ríos Burrows, N., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2207018 · Cited by 109
Boer, I. H. D., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., & Bakris, G. (2022) · doi:10.2337/figshare.20272404.v1 · Cited by 79
Neuen, B. L., Ohkuma, T., Neal, B., Matthews, D. R., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Blais, J., Li, Q., Jardine, M. J., et al. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.06.018 · Cited by 70
Kibria, G. M. A., & Crispen, R. (2020) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2020.101193 · Cited by 64
FLOW trial stopped early due to evidence of renal protection with semaglutide
Gragnano, F., De Sio, V., & Calabrò, P. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad080 · Cited by 51 · cited 1×
“The FLOW trial of semaglu-tide in participants with CKD (UACR >100 mg/g) and T2DM was stopped prematurely owing to efficacy for kidney, cardiovascular and all-cause mortality outcomes 160,163,164 .”
Healthy and unhealthy aging on kidney structure and function: human studies
Denic, A., Rule, A. D., & Glassock, R. J. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000780 · Cited by 20
Cited by
Mark, P. B., Stafford, L. K., Grams, M. E., Aalruz, H., Abd ElHafeez, S., Abdelgalil, A. A., Abdulkader, R. S., Abeywickrama, H. M., Abiodun, O. O., Abramov, D., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01853-7 · Cited by 418
Self-citation
Metadata
- Authors
- Chesnaye, N. C., Ortiz, A., Zoccali, C., Stel, V. S., & Jager, K. J.
- Venue
- Nature Reviews Nephrology
- Published
- 2024-07-18
- Volume
- 20
- Issue
- 9
- Pages
- 569-585
- ISSN
- 1745-8323 (ISSN-L)
- 1759-5061
- 1759-507X
- OpenAlex
- W4400776379
- Cited by
- 171
- References
- 50
- FWCI
- 16.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.